Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement.
Ontology highlight
ABSTRACT: Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis characterized by infiltration of organs by CD68+ and CD1a- lipid-laden histiocytes, including the central nervous system in more than a third of patients. Molecular analysis of ECD samples has demonstrated the prevalence of BRAF V600E mutations as high as 54%. Recently, vemurafenib became the only Food and Drug Administration-approved treatment for patients with ECD who carry the BRAF V600E mutation. However, dabrafenib has been suggested to have greater brain distribution. We describe a 44-year-old female patient treated from August of 2015 through November 2017. She presented with a 2-year history of light-headedness, fatigue, and vertigo. She was moderately dysmetric, di
SUBMITTER: Al Bayati A
PROVIDER: S-EPMC6132217 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA